Multi-centre Clinical Trial on Hormone Replacement Treatment in China
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Change from Baseline in risk factors of cardiovascular disease at 12 months and 24 months
lipid profiles, high-sensitivity C-reactive protein, Hemoglobin A1C, fasting glucose, fasting insulin, blood pressure, waistline, hipline, body composition, electrocardiogram, incidence of coronary heart disease
before the treatment, time point of taking the medicine for 1 year, time point of taking the medicine for 2 years
Yes
Aijun Sun, PH.D M.D
Study Director
Peking Union Medical College Hospital
China: Ministry of Health
2008BAI57B04
NCT01698164
December 2008
Name | Location |
---|